European regulators probe suicide risk to Ozempic, other Novo drug Saxenda

European Union regulators are examining whether people taking Novo Nordisk’s diabetes and weight-loss drug Ozempic are at higher risk of having thoughts of suicide or self-harm. The European Medicines Agency’s drug safety panel is basing its probe on three cases reported by Iceland’s drug regulator, the EMA said.